Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025

Core Insights - Enlivex Therapeutics Ltd. will present a late-breaking poster abstract at the American College of Rheumatology (ACR) Convergence 2025, showcasing clinical data from a Phase IIa trial of Allocetra™ for knee osteoarthritis [1][2]. Company Overview - Enlivex is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™, a universal cell therapy aimed at reprogramming macrophages to restore immune balance [5]. Clinical Trial Details - The Phase IIa trial (ENX-CL-05-001) demonstrated significant improvements in pain reduction and functional enhancement in patients with moderate-to-severe knee osteoarthritis, particularly in those aged 60 and above, who represent over 50% of the KOA market [2]. - The trial results will be presented by Prof. Philip Conaghan, a leading expert in osteoarthritis, highlighting the credibility of the findings [2]. Presentation Information - The poster presentation is scheduled for October 28, 2025, from 10:30 AM to 12:30 PM CT, under the title "Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis" [7]. Conference Participation - Einat Galamidi, MD, the Chief Medical Officer, will attend the ACR conference and is available for meetings with stakeholders and the scientific community [4].